Clinical trials: Esophageal Cancer Metastatic
Esophageal Cancer
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093652
- Testing
- gefitinib, oxaliplatin, conventional surgery
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002984
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma Metastatic
A Study of SBRT for OligoMetastatic ESCC
The aim of this phase II trial is to assess progress-free survival, local control, overall survival, safety and tolerability of SBRT to treat patients with oligometastases in esophageal squamous cell carcinoma.
- Trial name
- NCT03000816
- Testing
- SBRT
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer
RATIONALE: Analgesics, antiemetics, steroids, and radiation therapy are effective in helping to control symptoms caused by cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer, Nausea and Vomiting
- Trial name
- NCT00978549
- Testing
- docetaxel, steroid therapy, questionnaire administration
- Where
- 8 sites in United Kingdom
- Volunteers
- 320 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
ESCC or Esophageal Adenosquamous Carcinoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC
This study is conducted in patients with Locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) or esophageal adenosquamous carcinoma. This study includes three arms: A, B1, and B2.
- Trial name
- NCT05221658
- Testing
- HLX07+HLX10+ Cisplatin+5-FU, HLX07
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Gastro-esophageal Junction Cancer
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with…
- Conditions
- Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06005493
- Testing
- AZD5863, AZD2936
- Where
- 25 sites in United States, China and 6 more
- Volunteers
- 392 people
- Sponsor
- AstraZeneca
Esophageal Cancer, Oesophageal Cancer
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
Cancer - including esophageal squamous cell cancer (ESCC) - is a disease of the elderly but little is known about the biology and progression of cancers in these patients.
- Conditions
- Esophageal Cancer, Oesophageal Cancer, Oesophageal Cancer Metastatic, Esophageal Cancer Metastatic
- Trial name
- RAMONA (NCT03416244)
- Testing
- Nivolumab, Ipilimumab
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- AIO-Studien-gGmbH
Esophageal Cancer
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00381706
- Testing
- cetuximab, ECF, IC
- Where
- 227 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastro-entero-pancreatic Carcinoma, Esophageal Neuroendocrine Carcinoma
Octreotide LAR as Maintenance Treatment for Patients With NEC
This is phase II study on the efficacy of octreotide lar as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas.
- Trial name
- NCT02409849
- Testing
- Octreotide lar
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Peking University
Esophagus Cancer
Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics
This study proposes to establish a CT radiomics-based prediction model for identifying metastasis lymph nodes in esophageal cancer.
- Trial name
- NCT03237130
- Testing
- preoperative enhanced chest CT examination
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Prostatic Neoplasms, Esophageal Neoplasms
Tumor Hypoxia With HX4 PET in Several Diseases
Regulation of tissue oxygen homeostasis is critical for cell function, proliferation and survival. Evidence for this continues to accumulate along with our understanding of the complex oxygen-sensing pathways present within…
- Conditions
- Prostatic Neoplasms, Esophageal Neoplasms, Neoplasm Metastases, Brain, Rectal Neoplasms
- Trial name
- HX4 SD (NCT02584400)
- Testing
- Injection with the hypoxia tracer [18F]HX4,
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- Maastricht Radiation Oncology
Esophageal Squamous Cell Carcinoma (ESCC)
Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
This is a multicenter, retrospective observational study using existing medical records of patients with esophageal squamous cell carcinoma who received at least two cycles of neoadjuvant immunochemotherapy followed by curative…
- Trial name
- NCT07705412
- Testing
- Postoperative Radiotherapy, Lymph Node Dissection
- Where
- China
- Volunteers
- 465 people
- Sponsor
- Tongji Hospital
Locally Advanced or Metastatic Malignant Solid Tumors
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
- Trial name
- NCT04225117
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
The study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.
- Trial name
- NCT07790380
- Testing
- FH-006, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Squamous Cell Carcinoma (ESCC)
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The purpose of this study is to assess the efficacy and safety of QL1706 plus lenvatinib in second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor…
- Trial name
- NCT06746961
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib
- Volunteers
- 49 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University